Breast Cancer Research and Treatment

, Volume 108, Issue 1, pp 23–33 | Cite as

Transactivation of ERα by Rosiglitazone induces proliferation in breast cancer cells

  • Dominique R. Talbert
  • Clinton D. Allred
  • Yekaterina Y. Zaytseva
  • Michael W. Kilgore
Preclinical Study


In the present study, we demonstrate that Rosiglitazone (Rosi), a thiazolidinedione and PPARγ agonist, induces ERE (Estrogen Receptor Response Element) reporter activity, pS2 (an endogenous ER gene target) expression, and proliferation of ER positive breast cancer (MCF-7) cells. By performing a dose–response assay, we determined that high concentrations of Rosi inhibit proliferation, while low concentrations of Rosi induce proliferation. Using the anti-estrogen ICI, ER negative breast cancer (MDA-MB-231) cells, and a prostate cancer cell line (22Rv1) deficient in both ERα and PPARγ, we determined that Rosiglitazone-induced ERE reporter activation and proliferation is through an ERα dependent mechanism. Rosiglitazone-induced ERE activation is also dependent on activation of the Extracellular Signal-Regulated Kinase–Mitogen Activated Protein Kinase (ERK–MAPK) pathway, since it is inhibited by co-treatment with U0126, a specific inhibitor of this pathway. We also demonstrate that when ERα and PPARγ are both present, they compete for Rosi, inhibiting each others transactivation. To begin to unravel the pharmacological mechanism of Rosi-induced ER activation, sub-maximally effective concentrations of E2 were used in combination with increasing concentrations of Rosi in luciferase reporter assays. From these assays it appears that E2 and Rosi both activate ERα via similar pharmacological mechanisms. Furthermore sub-maximally effective concentrations of E2 and Rosi additively increase both ERE reporter activity and MCF-7 cell proliferation. The results of this study may have clinical relevancy for Rosi’s use both as an anti-diabetic in post-menopausal women and as an anti-cancer drug in women with ER positive breast cancer


PPARγ ERα Crosstalk Breast cancer Rosiglitazone 



Grant Support: This work was supported by 1F31CA117235 from the NIH to DT, W81XWH-04-01-0532 from the Department of Defense to CDA and 5-K12-DA-14040-02, NCRR-P20-RR15592, and R01-CA95609 from the NIH to MWK.


  1. 1.
    Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–12956PubMedCrossRefGoogle Scholar
  2. 2.
    Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedCrossRefGoogle Scholar
  3. 3.
    Issemann I, Prince RA, Tugwood JD, Green S (1993) The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie 75:251–256PubMedCrossRefGoogle Scholar
  4. 4.
    Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S (1992) The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11:433–439PubMedGoogle Scholar
  5. 5.
    Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994) Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455–1458PubMedCrossRefGoogle Scholar
  6. 6.
    Meyer ME, Gronemeyer H, Turcotte B, Bocquel MT, Tasset D, Chambon P (1989) Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57:433–442PubMedCrossRefGoogle Scholar
  7. 7.
    Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234PubMedCrossRefGoogle Scholar
  8. 8.
    Kilgore MW, Tate PL, Rai S, Sengoku E, Price TM (1997) MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol Cell Endocrinol 129:229–235PubMedCrossRefGoogle Scholar
  9. 9.
    Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614–7619PubMedCrossRefGoogle Scholar
  10. 10.
    Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789PubMedCrossRefGoogle Scholar
  11. 11.
    Thoennes SR, Tate PL, Price TM, Kilgore MW (2000) Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol Cell Endocrinol 160:67–73PubMedCrossRefGoogle Scholar
  12. 12.
    Issemann I, Prince RA, Tugwood JD, Green S (1993) The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 11:37–47PubMedGoogle Scholar
  13. 13.
    Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819PubMedCrossRefGoogle Scholar
  14. 14.
    Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803–812PubMedCrossRefGoogle Scholar
  15. 15.
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406–3410PubMedCrossRefGoogle Scholar
  16. 16.
    Wang X, Southard RC, Kilgore MW (2004) The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res 64:5592–5596PubMedCrossRefGoogle Scholar
  17. 17.
    Nwankwo JO, Robbins ME (2001) Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64:241–245PubMedCrossRefGoogle Scholar
  18. 18.
    Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP (1998) Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806–8811PubMedCrossRefGoogle Scholar
  19. 19.
    Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465–470PubMedCrossRefGoogle Scholar
  20. 20.
    Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM (2004) PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18:528–540PubMedCrossRefGoogle Scholar
  21. 21.
    Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951–3956PubMedCrossRefGoogle Scholar
  22. 22.
    Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP (2003) Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79:391–397PubMedCrossRefGoogle Scholar
  23. 23.
    Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289PubMedCrossRefGoogle Scholar
  24. 24.
    Martin PM, Rolland PH, Jacquemier J, Rolland AM, Toga M (1979) Multiple steroid receptors in human breast cancer. II. Estrogen and progestin receptors in 672 primary tumors. Cancer Chemother Pharmacol 2:107–113PubMedCrossRefGoogle Scholar
  25. 25.
    Keller H, Givel F, Perroud M, Wahli W (1995) Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 9:794–804PubMedCrossRefGoogle Scholar
  26. 26.
    Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Ando S (2005) Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 11:6139–6147PubMedCrossRefGoogle Scholar
  27. 27.
    Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S (2003) Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63:958–964PubMedGoogle Scholar
  28. 28.
    Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, Ishida T, Ohuchi N, Sasano H (2006) Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 13:233–250PubMedCrossRefGoogle Scholar
  29. 29.
    Wang X, Kilgore MW (2002) Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 194:123–133PubMedCrossRefGoogle Scholar
  30. 30.
    Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET (2002) Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am J Physiol Endocrinol Metab 282:E891–E898PubMedGoogle Scholar
  31. 31.
    Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinmoa cell line. In Vitro Cell Dev Biol Anim 35:403–409Google Scholar
  32. 32.
    Gunin AG, Bitter AD, Demakov AB, Vasilieva EN, Suslonova NV (2004) Effects of peroxisome proliferator activated receptors-alpha and gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol 182:229–239PubMedCrossRefGoogle Scholar
  33. 33.
    Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH (2001) Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Invest Med 49:413–420CrossRefGoogle Scholar
  34. 34.
    Seargent JM, Yates EA, Gill JH (2004) GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 143:933–937PubMedCrossRefGoogle Scholar
  35. 35.
    Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB (2002) MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21:4000–4008PubMedCrossRefGoogle Scholar
  36. 36.
    Camp HS, Tafuri SR (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 272:10811–10816PubMedCrossRefGoogle Scholar
  37. 37.
    Baek SJ, Wilson LC, Hsi LC, Eling TE (2003) Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278:5845–5853PubMedCrossRefGoogle Scholar
  38. 38.
    Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R (2002) Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 20:1809–1817PubMedCrossRefGoogle Scholar
  39. 39.
    Lonning PE, Geisler J, Johannessen DC, Ekse D (1997) Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 61:255–260PubMedCrossRefGoogle Scholar
  40. 40.
    Yue W, Santen RJ, Wang JP, Hamilton CJ, Demers LM (1999) Aromatase within the breast. Endocr Relat Cancer 6:157–164PubMedCrossRefGoogle Scholar
  41. 41.
    Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, Eng C (2007) Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13:246–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Dominique R. Talbert
    • 1
  • Clinton D. Allred
    • 2
  • Yekaterina Y. Zaytseva
    • 1
  • Michael W. Kilgore
    • 1
  1. 1.Department of Molecular and Biomedical PharmacologyUniversity of Kentucky College of MedicineLexingtonUSA
  2. 2.Nutrition and Food ScienceTexas A&M UniversityCollege StationUSA

Personalised recommendations